These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24322734)

  • 21. Virus-like particles produced in plants as potential vaccines.
    Scotti N; Rybicki EP
    Expert Rev Vaccines; 2013 Feb; 12(2):211-24. PubMed ID: 23414411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matrix and backstage: cellular substrates for viral vaccines.
    Jordan I; Sandig V
    Viruses; 2014 Apr; 6(4):1672-700. PubMed ID: 24732259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The synthetic futures of vesicular stomatitis virus.
    Overend C; Yuan L; Peccoud J
    Trends Biotechnol; 2012 Oct; 30(10):497-8. PubMed ID: 22789133
    [No Abstract]   [Full Text] [Related]  

  • 24. Future directions for the development of Chlamydomonas-based vaccines.
    Rosales-Mendoza S
    Expert Rev Vaccines; 2013 Sep; 12(9):1011-9. PubMed ID: 24053395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eighth Korea-Japan Chemical Biology symposium: chemical biology notes from a small island.
    Schneider-Poetsch T; Takahashi S; Jang JH; Ahn JS; Osada H
    J Antibiot (Tokyo); 2016 Dec; 69(12):885-888. PubMed ID: 27245557
    [No Abstract]   [Full Text] [Related]  

  • 26. Letter from the editor.
    Ellis RW; Riedmann EM
    Hum Vaccin Immunother; 2014; 10(8):2137-8. PubMed ID: 25424915
    [No Abstract]   [Full Text] [Related]  

  • 27. [Idiotypic vaccines].
    Rymkiewicz D; Wysokińska T
    Przegl Epidemiol; 1990; 44(4):337-40. PubMed ID: 2100818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development.
    den Engelsman J; Garidel P; Smulders R; Koll H; Smith B; Bassarab S; Seidl A; Hainzl O; Jiskoot W
    Pharm Res; 2011 Apr; 28(4):920-33. PubMed ID: 20972611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel TB vaccine; towards a strategy based on our understanding of BCG failure.
    Agger EM; Andersen P
    Vaccine; 2002 Nov; 21(1-2):7-14. PubMed ID: 12443657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Technologies for the design, discovery, formulation and administration of vaccines.
    Ellis RW
    Vaccine; 2001 Mar; 19(17-19):2681-7. PubMed ID: 11257409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Letter from the editor.
    Ellis R; Riedmann EM
    Hum Vaccin Immunother; 2014; 10(7):1771-2. PubMed ID: 25424780
    [No Abstract]   [Full Text] [Related]  

  • 32. Biotechnology in the development of new vaccines and diagnostic reagents against tuberculosis.
    Mustafa AS
    Curr Pharm Biotechnol; 2001 Jun; 2(2):157-73. PubMed ID: 11480420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moving Helicobacter pylori vaccine development forward with bioinformatics and immunomics.
    Moise L; Moss SF; De Groot AS
    Expert Rev Vaccines; 2012 Sep; 11(9):1031-3. PubMed ID: 23151160
    [No Abstract]   [Full Text] [Related]  

  • 34. The feasibility of a novel bioreactor for vaccine production of classical swine fever virus.
    Wu SC; Liau MY; Lin YC; Sun CJ; Wang CT
    Vaccine; 2013 Jan; 31(6):867-72. PubMed ID: 23261041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influenza vaccine innovation system and lessons for PDPs.
    Huzair F
    Hum Vaccin Immunother; 2012 Mar; 8(3):407-10. PubMed ID: 22327495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccines: facing complex problems with the promise of immunology.
    Plotkin SA; Rees J
    Expert Rev Vaccines; 2014 Aug; 13(8):939-41. PubMed ID: 24972860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Newcastle disease virus outbreaks in India: Time to revisit the vaccine type and strategies.
    Kumar S
    Vaccine; 2015 Jun; 33(29):3268-9. PubMed ID: 25769210
    [No Abstract]   [Full Text] [Related]  

  • 38. The application of virus-like particles to human diseases.
    Buonaguro F; Buonaguro L
    Expert Rev Vaccines; 2013 Feb; 12(2):99. PubMed ID: 23414399
    [No Abstract]   [Full Text] [Related]  

  • 39. Developing vaccines in the era of genomics: a decade of reverse vaccinology.
    Seib KL; Zhao X; Rappuoli R
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():109-16. PubMed ID: 22882709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unlocking the potential of natural products in drug discovery.
    Wright GD
    Microb Biotechnol; 2019 Jan; 12(1):55-57. PubMed ID: 30565871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.